Earnings ·
Prestige Consumer Healthcare Inc. reported first-quarter fiscal 2027 results ending June 30, 2026, with revenue of…
PBHPrestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. reported first-quarter fiscal 2027 results ending June 30, 2026, with revenue of $265.7 million, a 6.5% increase year-over-year, driven by organic growth of 3.2% and contributions from the Breathe Right acquisition. Adjusted diluted EPS was $0.98, up from $0.95 in the prior year period, while adjusted free cash flow reached a record $83.7 million. The company closed its acquisitions of the Breathe Right portfolio and LaCorium Health in June and July 2026, respectively, adding approximately $190 million to expected annual revenue. Consequently, Prestige raised its full-year fiscal 2027 outlook, projecting revenue between $1,290 million and $1,315 million and adjusted diluted EPS between $4.55 and $4.65. The company operates in the consumer healthcare industry, marketing and distributing over-the-counter health products including brands such as Breathe Right, Monistat, and Clear Eyes.